bloodjourГематология и трансфузиологияRussian journal of hematology and transfusiology0234-57302411-3042ООО Издательский дом «Практика»10.35754/0234-5730-2022-67-3-419-425bloodjour-389Research ArticleОБЗОРЫREVIEWSЗначение определения плазменной концентрации фактора фон Виллебранда в прогнозировании риска инсульта у больных с фибрилляцией предсердийThe role of estimation of plasma von Willebrand factor concentration in stroke risk stratification in patients with atrial fibrillationhttps://orcid.org/0000-0002-3996-4689РубаненкоА. О.RubanenkoA. O.

Рубаненко Анатолий Олегович, кандидат медицинских наук, доцент кафедры пропедевтической терапии

443099, Самара

Anatolii O. Rubanenko, Cand. Sci. (Med.), Associate Professor of the Department of Propaedeutic Therapy

443099, Samara

anatolii.rubanenko@gmail.comhttps://orcid.org/0000-0001-9351-6177РубаненкоО. А.RubanenkoO. A.

Рубаненко Олеся Анатольевна, доктор медицинских наук, доцент кафедры госпитальной терапии с курсами поликлинической терапии и трансфузиологии

443099, Самара

Olesya A. Rubanenko, Dr. Sci. (Med.), Associate Professor of the Department of Hospital Therapy with Courses of Polyclinic Therapy and Transfusiology

443099, Samara

olesya.rubanenko@gmail.comФГБОУ ВО «Самарский государственный медицинский университет» Министерства здравоохранения Российской ФедерацииРоссияSamara State Medical UniversityRussian Federation202222102022673419425Copyright © Рубаненко А.О., Рубаненко О.А., 20222022Рубаненко А.О., Рубаненко О.А.Rubanenko A.O., Rubanenko O.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.htjournal.ru/jour/article/view/389Введение

Введение. Фактор фон Виллебранда (von Willebrand Factor, vWF) — крупный многомерный плазменный гликопротеин, играющий большую роль в гемостазе. Данный показатель не включен в современные шкалы стратификации риска инсульта у больных с фибрилляцией предсердий (ФП).

Цель — оценить возможность использования изменений концентрации vWF для стратификации риска инсульта у больных с ФП.

Основные сведения

Основные сведения. vWF относится к числу важных предикторов развития инсульта у больных с ФП, что подтверждается результатами метаанализа, включившего 12 исследований и 7449 больных с ФП. Определение концентрации vWF у больных, имеющих низкий риск развития инсульта по шкале CHA2DS2-VASc, или у больных, которые набирают один балл, не связанный с полом, может быть полезным при решении вопроса о назначении антикоагулянтной терапии.

Introduction

Introduction. Von Willebrand factor (vWF) is a large plasma glycoprotein that plays a major role in hemostasis. The vWF plasma concentration is not included in modern stoke risk stratification scales in patients with atrial fibrillation (AF).

Aim — to evaluate the possibility of usage of vWF plasma concentration in stroke risk stratification in patients with atrial fibrillation.

General findings

General findings. vWF is an important predictor of stroke development in patients with AF based on the results of the conducted meta-analysis that included 12 studies and 7449 patients with AF. Determining the concentration of vWF in patients with low risk of stroke development or in those patients with a single non-sex CHA2DS2-VASc score risk factor may be useful in deciding whether to prescribe anticoagulant therapy.

фактор Виллебрандафибрилляция предсердийинсультпрогнозированиеvon Willebrand factoratrial fibrillationstrokeprognosisReferencesEchahdi H., El Hasbaoui B., El Khorassani M., et al. Von Willebrand’s disease: Case report and review of literature. Pan Afr Med J. 2017; 27: 147. DOI: 10.11604/pamj.2017.27.147.12248.Echahdi H., El Hasbaoui B., El Khorassani M., et al. Von Willebrand’s disease: Case report and review of literature. Pan Afr Med J. 2017; 27: 147. DOI: 10.11604/pamj.2017.27.147.12248.Чернецкая Д.М., Лихачева Е.А., Пшеничникова О.С. и др. Болезнь Виллебранда: сопоставление клинических, коагулогических и молекулярногенетических данных. Гематология и трансфузиология. 2019; 64(3): 246–55. DOI: 10.35754/0234-5730-2019-64-3-246-255.Chernetskaya D.M., Likhacheva E.A., Pshenichnikova O.S., et al. Von Willebrand disease: Clinical, coagulogical, molecular and genetic data comparison. Gematologiya i Transfusiologiya. 2019; 64(3): 246–55. DOI: 10.35754/02345730-2019-64-3-246-255. (In Russian).Manon-Jensen T., Kjeld N.G., Karsdal M.A. Collagen-mediated hemostasis. J Thromb Haemost. 2016; 14(3): 438–48. DOI: 10.1111/jth.13249.Manon-Jensen T., Kjeld N.G., Karsdal M.A. Collagen-mediated hemostasis. J Thromb Haemost. 2016; 14(3): 438–48. DOI: 10.1111/jth.13249.Chen J., Chung D.W. Inflammation, von Willebrand factor, and ADAMTS13. Blood. 2018; 132(2): 141–7. DOI: 10.1182/blood-2018-02-769000.Chen J., Chung D.W. Inflammation, von Willebrand factor, and ADAMTS13. Blood. 2018; 132(2): 141–7. DOI: 10.1182/blood-2018-02-769000.Степанова Т.В., Иванов А.Н., Терешкина Н.Е. и др. Маркеры эндотелиальной дисфункции: патогенетическая роль и диагностическое значение (обзор литературы). Клиническая лабораторная диагностика. 2019; 64(1): 34–41. DOI: 10.18821/0869-2084-2019-64-1-34-41.Stepanova T.V., Ivanov A.N., Tereshkina N.E., et al. Markers of endothelial dysfunction: Pathogenetic role and diagnostic significance. Klinicheskaya laboratornaya diagnostika. 2019; 64(1): 34–41. DOI: 10.18821/0869-2084-201964-1-34-41. (In Russian).Zeineddin A., Dong J.F., Wu F., et al. Role of von Willebrand factor after in jury: It may do more than we think. Shock. 2021; 55(6): 717–22. DOI: 10.1097/ SHK.0000000000001690.Zeineddin A., Dong J.F., Wu F., et al. Role of von Willebrand factor after in jury: It may do more than we think. Shock. 2021; 55(6): 717–22. DOI: 10.1097/ SHK.0000000000001690.Barac A., Campia U., Panza J.A. Methods for evaluating endothelial function in humans. Hypertension. 2007; 49(4): 748–60. DOI: 10.1161/01. HYP.0000259601.38807.a6.Barac A., Campia U., Panza J.A. Methods for evaluating endothelial function in humans. Hypertension. 2007; 49(4): 748–60. DOI: 10.1161/01. HYP.0000259601.38807.a6.Flood V.H., Schlauderaff A.C., Haberichter S.L., et al. Crucial role for the vWF A1 domain in binding to type IV collagen. Blood. 2015; 125(14): 2297–304. DOI: 10.1182/blood-2014-11-610824.Flood V.H., Schlauderaff A.C., Haberichter S.L., et al. Crucial role for the vWF A1 domain in binding to type IV collagen. Blood. 2015; 125(14): 2297–304. DOI: 10.1182/blood-2014-11-610824.Bryckaert M., Rosa J.P., Denis C.V., Lenting PJ. Of von Willebrand factor and platelets. Cell Mol Life Sci. 2015; 72(2): 307–26. DOI: 10.1007/s00018-0141743-8.Bryckaert M., Rosa J.P., Denis C.V., Lenting PJ. Of von Willebrand factor and platelets. Cell Mol Life Sci. 2015; 72(2): 307–26. DOI: 10.1007/s00018-0141743-8.Колосков А.В., Мангушло А.А. Металлопротеаза ADAMTS-13. Гематология и трансфузиология. 2019; 64(4): 471–82. DOI: 10.35754/02345730-2019-64-4-471-482.Koloskov A.V., Mangushlo A.A. Metalloprotease ADAMTS-13. Gematologiya i transfuziologiya. 2019; 64(4): 471–82. DOI: 10.35754/0234-5730-201964-4-471-482. (In Russian).Watson T., Shantsila E., Lip GY. Mechanisms of thrombogenesis in atrial fibrillation: Virchow’s triad revisited. Lancet. 2009; 373(9658): 155–66. DOI: 10.1016/ S0140-6736(09)60040-4.Watson T., Shantsila E., Lip GY. Mechanisms of thrombogenesis in atrial fibrillation: Virchow’s triad revisited. Lancet. 2009; 373(9658): 155–66. DOI: 10.1016/ S0140-6736(09)60040-4.Hindricks G., Potpara T., Dagres N., et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J. 2021; 42(5): 373–498. DOI: 10.1093/eurheartj/ehaa612.Hindricks G., Potpara T., Dagres N., et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J. 2021; 42(5): 373–498. DOI: 10.1093/eurheartj/ehaa612.Zhu W., Fu L., Ding Y., et al. Meta-analysis of ATRIA versus CHA2DS2-VASc for predicting stroke and thromboembolism in patients with atrial fibrillation. Int J Cardiol. 2017; 227: 436–42. DOI: 10.1016/j.ijcard.2016.11.015.Zhu W., Fu L., Ding Y., et al. Meta-analysis of ATRIA versus CHA2DS2-VASc for predicting stroke and thromboembolism in patients with atrial fibrillation. Int J Cardiol. 2017; 227: 436–42. DOI: 10.1016/j.ijcard.2016.11.015.Singer D.E., Chang Y., Borowsky L.H., et al. A new risk scheme to predict is chemic stroke and other thromboembolism in atrial fibrillation: The ATRIA study stroke risk score. J Am Heart Assoc. 2013; 2(3): e000250. DOI: 10.1161/ JAHA.113.000250.Singer D.E., Chang Y., Borowsky L.H., et al. A new risk scheme to predict is chemic stroke and other thromboembolism in atrial fibrillation: The ATRIA study stroke risk score. J Am Heart Assoc. 2013; 2(3): e000250. DOI: 10.1161/JAHA.113.000250.Graves K.G., May H.T., Knowlton K.U., et al. Improving CHA2DS2-VASc stratification of non-fatal stroke and mortality risk using the Intermountain Mortality Risk Score among patients with atrial fibrillation. Open Heart. 2018; 5(2): e000907. DOI: 10.1136/openhrt-2018-000907.Graves K.G., May H.T., Knowlton K.U., et al. Improving CHA2DS2-VASc stratification of non-fatal stroke and mortality risk using the Intermountain Mortality Risk Score among patients with atrial fibrillation. Open Heart. 2018; 5(2): e000907. DOI: 10.1136/openhrt-2018-000907.Hijazi Z., Lindbäck J., Alexander J.H., et al. ARISTOTLE and STABILITY Investigators. The ABC (age, biomarkers, clinical history) stroke risk score: A biomarkerbased risk score for predicting stroke in atrial fibrillation. Eur Heart J. 2016; 37(20): 1582–90. DOI: 10.1093/eurheartj/ehw054.Hijazi Z., Lindbäck J., Alexander J.H., et al. ARISTOTLE and STABILITY Investigators. The ABC (age, biomarkers, clinical history) stroke risk score: A biomarkerbased risk score for predicting stroke in atrial fibrillation. Eur Heart J. 2016; 37(20): 1582–90. DOI: 10.1093/eurheartj/ehw054.Alonso A., Tang W., Agarwal S.K., et al. Hemostatic markers are associated with the risk and prognosis of atrial fibrillation: The ARIC study. Int J Cardiol. 2012; 155(2): 217–22. DOI: 10.1016/j.ijcard.2010.09.051.Alonso A., Tang W., Agarwal S.K., et al. Hemostatic markers are associated with the risk and prognosis of atrial fibrillation: The ARIC study. Int J Cardiol. 2012; 155(2): 217–22. DOI: 10.1016/j.ijcard.2010.09.051.Roldan V., Marín F., Muina B., et al. Plasma von Willebrand factor levels are an in dependent risk factor for adverse events in cluding mortality and major bleeding in anticoagulated atrial fibrillation patients. J Am Coll Cardiol. 2011; 57(25): 2496–504. DOI: 10.1016/j.jacc.2010.12.033.Roldan V., Marín F., Muina B., et al. Plasma von Willebrand factor levels are an in dependent risk factor for adverse events in cluding mortality and major bleeding in anticoagulated atrial fibrillation patients. J Am Coll Cardiol. 2011; 57(25): 2496–504. DOI: 10.1016/j.jacc.2010.12.033.Ancedy Y., Berthelot E., Lang S., et al. Is von Willebrand factor associated with stroke and death at mid-term in patients with non-valvular atrial fibrillation? Arch Cardiovasc Dis. 2018; 111(5): 357–69. DOI: 10.1016/j.acvd.2017.08.004.Ancedy Y., Berthelot E., Lang S., et al. Is von Willebrand factor associated with stroke and death at mid-term in patients with non-valvular atrial fibrillation? Arch Cardiovasc Dis. 2018; 111(5): 357–69. DOI: 10.1016/j.acvd.2017.08.004.García-Fernandez A., Roldan V., Rivera-Caravaca J.M., et al. Does von Willebrand factor improve the predictive ability of current risk stratification scores in patients with atrial fibrillation? Sci Rep. 2017; 7: 41565. DOI: 10.1038/srep41565.García-Fernandez A., Roldan V., Rivera-Caravaca J.M., et al. Does von Willebrand factor improve the predictive ability of current risk stratification scores in patients with atrial fibrillation? Sci Rep. 2017; 7: 41565. DOI: 10.1038/srep41565.Krishnamoorthy S., Khoo C.W., Lim H.S. Prognostic role of plasma von Willebrand factor and soluble E-selectin levels for future cardiovascular events in a real-world community cohort of patients with atrial fibrillation. Eur J Clin Invest. 2013; 43(10): 1032–8. DOI: 10.1111/eci.12140.Krishnamoorthy S., Khoo C.W., Lim H.S. Prognostic role of plasma von Willebrand factor and soluble E-selectin levels for future cardiovascular events in a real-world community cohort of patients with atrial fibrillation. Eur J Clin Invest. 2013; 43(10): 1032–8. DOI: 10.1111/eci.12140.Hijazi Z., Oldgren J., Siegbahn A., Wallentin L. Application of biomarkers for risk stratification in patients with atrial fibrillation. Clin Chem. 2017; 63(1): 152– 64. DOI: 10.1373/clinchem.2016.255182.Hijazi Z., Oldgren J., Siegbahn A., Wallentin L. Application of biomarkers for risk stratification in patients with atrial fibrillation. Clin Chem. 2017; 63(1): 152– 64. DOI: 10.1373/clinchem.2016.255182.Wu N., Chen X., Cai T., et al. Association of inflammatory and hemostatic markers with stroke and thromboembolic events in atrial fibrillation: A systematic review and meta-analysis. Can J Cardiol. 2015; 31(3): 278–86. DOI: 10.1016/j.cjca.2014.12.002.Wu N., Chen X., Cai T., et al. Association of inflammatory and hemostatic markers with stroke and thromboembolic events in atrial fibrillation: A systematic review and meta-analysis. Can J Cardiol. 2015; 31(3): 278–86. DOI: 10.1016/j.cjca.2014.12.002.Zhong C., Xin M., He L. et al. Prognostic value of von Willebrand factor in patients with atrial fibrillation: A meta-analysis. Medicine. 2018; 97(27): e11269. DOI: 10.1097/MD.0000000000011269.Zhong C., Xin M., He L. et al. Prognostic value of von Willebrand factor in patients with atrial fibrillation: A meta-analysis. Medicine. 2018; 97(27): e11269. DOI: 10.1097/MD.0000000000011269.Ye Y.Z., Chang Y.F., Wang B.Z., et al. Prognostic value of von Willebrand factor for patients with atrial fibrillation: A meta-analysis of prospective cohort studies. Postgrad Med J. 2020; 96(1135): 267–76. DOI: 10.1136/postgradmedj-2019-136842.Ye Y.Z., Chang Y.F., Wang B.Z., et al. Prognostic value of von Willebrand factor for patients with atrial fibrillation: A meta-analysis of prospective cohort studies. Postgrad Med J. 2020; 96(1135): 267–76. DOI: 10.1136/postgradmedj-2019-136842.van Galen K.P., Tuinenburg A., Smeets E.M., Schutgens R.E. Von Willebrand factor deficiency and atherosclerosis. Blood Rev. 2012; 26(5): 189–96. DOI: 10.1016/j.blre.2012.05.002.van Galen K.P., Tuinenburg A., Smeets E.M., Schutgens R.E. Von Willebrand factor deficiency and atherosclerosis. Blood Rev. 2012; 26(5): 189–96. DOI: 10.1016/j.blre.2012.05.002.Hu Y.F., Chen Y.J., Lin Y.J. Chen S.A. Inflammation and the pathogenesis of atrial fibrillation. Nat Rev Cardiol. 2015; 12(4): 230–43. DOI: 10.1038/nrcardio.2015.2.Hu Y.F., Chen Y.J., Lin Y.J. Chen S.A. Inflammation and the pathogenesis of atrial fibrillation. Nat Rev Cardiol. 2015; 12(4): 230–43. DOI: 10.1038/nrcardio.2015.2.Karam B.S., Chavez-Moreno A., Koh W., et al. Oxidative stress and in flammation as central mediators of atrial fibrillation in obesity and diabetes. Cardiovasc Diabetol. 2017; 16(1): 120. DOI: 10.1186/s12933-017-0604-9.Karam B.S., Chavez-Moreno A., Koh W., et al. Oxidative stress and in flammation as central mediators of atrial fibrillation in obesity and diabetes. Cardiovasc Diabetol. 2017; 16(1): 120. DOI: 10.1186/s12933-017-0604-9.da Silva R.M. Influence of inflammation and atherosclerosis in atrial fibrillation. Curr Atheroscler Rep. 2017; 19(1): 2. DOI: 10.1007/s11883-017-0639-0.da Silva R.M. Influence of inflammation and atherosclerosis in atrial fibrillation. Curr Atheroscler Rep. 2017; 19(1): 2. DOI: 10.1007/s11883-017-0639-0.Jover E., Marín F., Roldan V., et al. Atherosclerosis and thromboembolic risk in atrial fibrillation: focus on peripheral vascular disease. Ann Med. 2013; 45(3): 274–90. DOI: 10.3109/07853890.2012.732702.Jover E., Marín F., Roldan V., et al. Atherosclerosis and thromboembolic risk in atrial fibrillation: focus on peripheral vascular disease. Ann Med. 2013; 45(3): 274–90. DOI: 10.3109/07853890.2012.732702.Peng X., Wang X., Fan M., et al. Plasma levels of von Willebrand factor in type 2 diabetes patients with and without cardiovascular diseases: A meta-analysis. Diabetes Metab Res Rev. 2020; 36(1): e3193. DOI: 10.1002/dmrr.3193.Peng X., Wang X., Fan M., et al. Plasma levels of von Willebrand factor in type 2 diabetes patients with and without cardiovascular diseases: A meta-analysis. Diabetes Metab Res Rev. 2020; 36(1): e3193. DOI: 10.1002/dmrr.3193.Small A.M., Huffman J.E., Klarin D., et al. Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) Hemostasis Working Group and the VA Million Veteran Program. Mendelian randomization analysis of hemostatic factors and the ir contribution to peripheral artery disease – brief report. Arterioscler Thromb Vasc Biol. 2021; 41(1): 380–6. DOI: 10.1161/ATVBAHA.119.313847.Small A.M., Huffman J.E., Klarin D., et al. Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) Hemostasis Working Group and the VA Million Veteran Program. Mendelian randomization analysis of hemostatic factors and the ir contribution to peripheral artery disease – brief report. Arterioscler Thromb Vasc Biol. 2021; 41(1): 380–6. DOI: 10.1161/ATVBAHA.119.313847.Favaloro E.J., Henry B.M., Lippi G. Increased vWF and Decreased ADAMTS-13 in COVID-19: Creating a milieu for (micro)thrombosis. Semin Thromb Hemost. 2021; 47(4): 400–18. DOI: 10.1055/s-0041-1727282.Favaloro E.J., Henry B.M., Lippi G. Increased vWF and Decreased ADAMTS-13 in COVID-19: Creating a milieu for (micro)thrombosis. Semin Thromb Hemost. 2021; 47(4): 400–18. DOI: 10.1055/s-0041-1727282.Pepin M., Kleinjan A., Hajage D. ADAMTS-13 and von Willebrand factor predict venous thromboembolism in patients with cancer. J Thromb Haemost. 2016; 14(2): 306–15. DOI: 10.1111/jth.13205.Pepin M., Kleinjan A., Hajage D. ADAMTS-13 and von Willebrand factor predict venous thromboembolism in patients with cancer. J Thromb Haemost. 2016; 14(2): 306–15. DOI: 10.1111/jth.13205.Maino A., Siegerink B., Lotta L.A., et al. Plasma ADAMTS-13 levels and the risk of myocardial in farction: An individual patient data meta-analysis. J Thromb Haemost. 2015; 13(8): 1396–404. DOI: 10.1111/jth.13032.Maino A., Siegerink B., Lotta L.A., et al. Plasma ADAMTS-13 levels and the risk of myocardial in farction: An individual patient data meta-analysis. J Thromb Haemost. 2015; 13(8): 1396–404. DOI: 10.1111/jth.13032.Wang H.J., Xiao M., Zeng Z. Correlation analysis between ADAMTS-13 gene polymorphism and hypertension-induced atrial fibrillation. Eur Rev Med Pharmacol Sci. 2020; 24(5): 2674–82. DOI: 10.26355/eurrev_202003_20537.Wang H.J., Xiao M., Zeng Z. Correlation analysis between ADAMTS-13 gene polymorphism and hypertension-induced atrial fibrillation. Eur Rev Med Pharmacol Sci. 2020; 24(5): 2674–82. DOI: 10.26355/eurrev_202003_20537Christersson C., Wallentin L., Andersson U., et al. Effect of apixaban compared with warfarin on coagulation markers in atrial fibrillation. Heart. 2019; 105(3): 235–42. DOI: 10.1136/heartjnl-2018-313351.Christersson C., Wallentin L., Andersson U., et al. Effect of apixaban compared with warfarin on coagulation markers in atrial fibrillation. Heart. 2019; 105(3): 235–42. DOI: 10.1136/heartjnl-2018-313351.

The authors declare that there are no conflicts of interest present.